Literature DB >> 1624030

Transvaginal intratubal methotrexate treatment of ectopic pregnancy.

T Tulandi1, M Atri, P Bret, T Falcone, S Khalife.   

Abstract

OBJECTIVE: To evaluate the efficacy of transvaginal intratubal methotrexate (MTX) treatment of tubal ectopic pregnancy (EP).
SETTING: Outpatient setting in University Hospital. PATIENTS: Forty women with early EP and rising serum beta-human chorionic gonadotropin (beta-hCG) levels. INTERVENTION: Transvaginal intratubal administration of MTX (1 mg/kg body weight). MAIN OUTCOME MEASURES: Success was defined as declining serum beta-hCG to undetectable levels, no tubal dilatation on ultrasound examination, and no further intervention was required.
RESULTS: Treatment was associated with a 70% success rate. No difference was found in the success rate between women with an embryo (76.9%) and those with no embryo in their fallopian tubes (66.7%). The initial serum beta-hCG levels were also not different between patients who were successfully treated and those who failed to respond to the treatment. Despite declining serum beta-hCG levels, tubal rupture occurred in two patients.
CONCLUSIONS: Treatment of EP by transvaginal MTX administration is associated with a 70% success rate. This is independent of the presence of an embryo or the initial serum beta-hCG levels. Rupture of EP can still occur despite low and declining serum beta-hCG levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1624030     DOI: 10.1016/s0015-0282(16)55143-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  The efficacy and safety of managing ectopic pregnancies with transvaginal ultrasound-guided local injections of absolute ethanol.

Authors:  Hirotsune Kaijima; Hisao Osada; Keiichi Kato; Tomoya Segawa; Yuji Takehara; Shokichi Teramoto; Osamu Kato
Journal:  J Assist Reprod Genet       Date:  2006-07-12       Impact factor: 3.412

2.  Methotrexate for the treatment of unruptured tubal pregnancy: a prospective nonrandomized study.

Authors:  Amélie Gervaise; Sylvie Capella-Allouc; François Audibert; Catherine Rongières-Bertrand; Yves Vincent; Hervè Fernandez
Journal:  JSLS       Date:  2003 Jul-Sep       Impact factor: 2.172

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.